Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (41-50 of 189) with videos related to

Pageof 19
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|August 7, 2013
The invisible arm of immunity in common cancer chemoprevention agentsEdmond Marzbani, Carol Inatsuka, Hailing Lu, et al.
Journal of Clinical Immunology|September 11, 2004
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patientsMary L Disis, Vivian Goodell, Kathy Schiffman, et al.
Cancer Research|February 12, 2004
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic miceKeith L Knutson, Bond Almand, Yushe Dang, et al.
Expert Review of Neurotherapeutics|October 9, 2009
Immunotherapy of glioblastoma multiformeKeith L Knutson, Lupe Salazar, Kathy Schiffman, et al.
Expert Review of Vaccines|March 26, 2011
ELISpot for measuring human immune responses to vaccinesMeredith Slota, Jong-Baeck Lim, Yushe Dang, et al.
Cancer Research|October 5, 2006
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigensHailing Lu, Keith L Knutson, Ekram Gad, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 19, 2021
Multimetric feature selection for analyzing multicategory outcomes of colorectal cancer: random forest and multinomial logistic regression modelsCatherine H Feng, Mary L Disis, Chao Cheng, et al.
Blood|February 8, 2007
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor responseLi-Xin Wang, Suyu Shu, Mary L Disis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Hematology/Oncology Clinics of North America|September 10, 2003
Immunologic principles and immunotherapeutic approaches in ovarian cancerKeith L Knutson, Tyler J Curiel, Lupe Salazar, et al.
Pageof 19

Showing results (41-50 of 189) with videos related to

Sort By:
Pageof 19
Cancer Prevention Research (Philadelphia, Pa.)|August 7, 2013
The invisible arm of immunity in common cancer chemoprevention agentsEdmond Marzbani, Carol Inatsuka, Hailing Lu, et al.
Journal of Clinical Immunology|September 11, 2004
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patientsMary L Disis, Vivian Goodell, Kathy Schiffman, et al.
Cancer Research|February 12, 2004
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic miceKeith L Knutson, Bond Almand, Yushe Dang, et al.
Expert Review of Neurotherapeutics|October 9, 2009
Immunotherapy of glioblastoma multiformeKeith L Knutson, Lupe Salazar, Kathy Schiffman, et al.
Expert Review of Vaccines|March 26, 2011
ELISpot for measuring human immune responses to vaccinesMeredith Slota, Jong-Baeck Lim, Yushe Dang, et al.
Cancer Research|October 5, 2006
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigensHailing Lu, Keith L Knutson, Ekram Gad, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 19, 2021
Multimetric feature selection for analyzing multicategory outcomes of colorectal cancer: random forest and multinomial logistic regression modelsCatherine H Feng, Mary L Disis, Chao Cheng, et al.
Blood|February 8, 2007
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor responseLi-Xin Wang, Suyu Shu, Mary L Disis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Hematology/Oncology Clinics of North America|September 10, 2003
Immunologic principles and immunotherapeutic approaches in ovarian cancerKeith L Knutson, Tyler J Curiel, Lupe Salazar, et al.
Pageof 19